Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2015

View Archived Issues

FDA grants QIDP status to WCK-5222

Vitae Pharmaceuticals begins phase IIa trial of VTP-38543 in atopic dermatitis

First subject dosed in phase I trial of TD-1473

COTI-2 advances into human testing

NORD receives FDA grant to study natural history of rare diseases

Preclinical efficacy of first-in-class TCB antibody EM-801

DMC recommends continuation of phase III trial of AGS-003 in RCC following second interim analysis

Janssen starts first-in-human trial of Aduro's ADU-214 in patients with NSCLC

Anti-HLA-DR antibody IMMU-114 demonstrates activity in first-in-human study

Burixafor/G-CSF promote impressive hematopoietic stem cell mobilization in MM, NHL and HL patients

Interim phase II data for isatuximab in refractory/relapsed multiple myeloma

Ularitide receives FDA fast track designation for acute decompensated heart failure

Agreements signed by Bristol-Myers Squibb, Kyorin, Novartis, Rhizen, AGTC and Synpromics

Ninlaro now available in the U.S.

Synergy seen with CDK9 inhibitors and venetoclax in lymphoma cells

ACE-083 increases muscle volume in phase I study

FDA approves Vistogard to treat overdose or severe toxicities due to 5-FU or capecitabine

GlaxoSmithKline patents ROR-gamma modulators

Mitsubishi Tanabe Pharma discloses MC1 receptor agonists

Novartis reports MALT1 inhibitors

Medshine Discovery introduces anti-HBV compounds

Pfizer discloses Nav1.7 channel blockers

Merck & Co. patents GPR40 agonists

Preclinical and clinical data reported for multiple myeloma candidate ACY-241

Chimeric antigen receptor-modified T cells induce partial remission in first AML patient treated

FDA grants accelerated approval to Alecensa

FDA approves Otiprio for pediatric patients undergoing tympanostomy tube placement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...